US 12,187,828 B2
Polymer excipients for biopharmaceutical formulations
Eric A. Appel, Palo Alto, CA (US); Caitlin Maikawa, Boston, MA (US); and Joseph L. Mann, Mountain View, CA (US)
Assigned to The Board of Trustees of the Leland Stanford Junior Univeristy, Stanford, CA (US)
Filed by The Board of Trustees of the Leland Stanford Junior University, Palo Alto, CA (US)
Filed on Mar. 31, 2023, as Appl. No. 18/129,811.
Application 18/129,811 is a division of application No. 17/962,252, filed on Oct. 7, 2022.
Application 17/962,252 is a continuation of application No. PCT/US2021/027693, filed on Apr. 16, 2021.
Claims priority of provisional application 63/159,306, filed on Mar. 10, 2021.
Claims priority of provisional application 63/011,928, filed on Apr. 17, 2020.
Prior Publication US 2023/0235109 A1, Jul. 27, 2023
Int. Cl. A61K 9/12 (2006.01); A61K 9/127 (2006.01); A61K 9/51 (2006.01); C08F 220/36 (2006.01)
CPC C08F 220/36 (2013.01) [A61K 9/1272 (2013.01); A61K 9/5146 (2013.01)] 55 Claims
OG exemplary drawing
 
1. A method for increasing the stability of an enzyme formulation, comprising adding 0.0005 wt % to 5 wt % of a polyacrylamide-based copolymer to the enzyme formulation;
wherein the polyacrylamide-based copolymer comprises:
a water-soluble carrier monomer selected from N-(3-methoxypropoyl)acrylamide (MPAM), 4-acryloylmorpholine (MORPH), N,N-dimethylacrylamide (DMA), N-hydroxyethyl acrylamide (HEAM), and acrylamide (AM); and
a functional dopant monomer selected from N-[tris(hydroxymethyl)-methyl] acrylamide (TRI), 2-acrylamido-2-methylpropane sulfonic acid (AMP), (3-acrylamidopropyl)trimethylammonium chloride (TMA), N-isopropylacrylamide (NIP), N-tertbutylacrylamide (TBA), and N-phenylacrylamide (PHE).